10 individually packed test cassettes for detection of the human complement factor H-related protein, (hCFHrp, bladder cancer antigen, BCA)) and hemoglobin (Hb) in urine
Package contents:
10 test cassettes
10 disposable pipettes
10 urine cups
10 caps for urine cups
1 package insert
Exclusively for professional users
Discover more than 2,000 medical and toxicological tests and POCT solutions
Please note: The prices shown are basic list prices. Your individual prices will be displayed after you have logged in to the shop. Your personal customer advisors can add them at any time.
The NADAL® BCA/Hb combo test is a simple one step immunochromatographic assay for the rapid qualitative detection of the human complement factor H-related protein, (hCFHrp bladder cancer antigen, BCA)) and hemoglobin (Hb) in urine. The test is intended to be used as an aid in the diagnosis of bladder cancer.
Carcinomas of the urinary bladder constitute approximately 2-3% of all malign tumours in humans. After prostatic carcinoma, bladder carcinoma is second in incidence of all tumour diseases of the genitourinary system. The factors increasing the risk of urinary bladder carcinoma include smoking, chronic cystitis, exposure in the workplace to carcinogens such as benzidine. The two most frequently used diagnostic procedures to detect a bladder carcinoma are urine cytology and cystoscopy. In urine cytology, urine sediments are investigated for cancer cells. Unfortunately, the total number of cells is frequently comparatively low. Moreover, the milieu conditions in urine attack cells and as a result, important diagnostic characteristics may be obscured. Hence, the main disadvantage of urine cytology is that clinical sensitivity is subject to considerable fluctuations and that tumors in early stages are often overlooked.
Due to its clinical sensitivity and specificity, cystoscopy is regarded as a standard diagnostic procedure (besides biopsy). The main disadvantages of cystoscopy are that it is an invasive intervention, which is strenuous for patients, and that only visible tumours are identified.
